PORTEFEUILLE

Every 9 min, a new patient is diagnosed with Parkinson’s disease, long considered incurable due to the irreversible loss of neurons in the brain. But today, there is hope, as it is now possible to produce these lost neurons from stem cells in the lab and to transplant them back into patients’ brains to restore their lives. However, current approaches are unscalable due to complicated production procedures and high costs, unsafe due to tumor risks, and unsustainable as many of the transplanted neurons eventually die in the brain. At AzureCell, leveraging decades of academic research and a portfolio of 5 patents, we’ve developed a groundbreaking approach that allows us to address these specific challenges, and to develop scalable, safe and long-lasting cell therapies for Parkinson’s.

With the support of the GRS InnoBooster grant, AzureCell aims to further develop and optimize its proprietary production process, a critical step that will significantly accelerate our path toward submitting our first regulatory package for clinical trials and therefore play a key role in expediting our market entry and patient impact.